Koutif Therapeutics, through a licensing relationship with the University of Pittsburgh, aims to develop therapeutic compounds that inhibits the inflammatory cascade in a unique manner. Our current lead compound is based upon discoveries by Rama Mallampalli, MD and Beibei Chen, PhD on inhibitors of the ubiquitin degradation pathway.
Inflammation plays a critical role in the progression of many diseases. One way of modulating this process is through the degradation of key proteins (TRAFs) involved in the activation cascade. Fbxo3, an E3 ligase, is a negative regulator of this control process resulting in a continuation of the inflammation cascade. Drs. Mallampalli and Chen identified a specific inhibitor of Fbxo3 that acts to allow the degradation of the TRAFs to occur resulting in a decrease in inflammation.
We have demonstrated in animal models of COPD that our technology is effective at inhibiting the inflammation cascade and symptoms of this disease. Furthermore, through genetic linkage experiments, a correlation between a specific genetic modification relevant to our technology’s mechanism of action and COPD was established.
Animal model experiments carried out with Fbxo3 inhibitor indicate that this pathway is also an attractive target for treating neuropathic pain (NP). NP is a large, global unmet medical need, with at least six million patients having NP in the seven major markets. The current move away from opioids for pain relief provides an opportunity for novel approaches in treatment for this disease.
Our technology is based on intellectual property exclusively licensed from the University of Pittsburgh and the United States Department of Veterans Affairs.